First National Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

First National Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,264	Closed	-$1.19M	–	163
2023 Q3	$1.19M	Buy	10,264 +4,087	+66%	+$439K	0.53%	66
2023 Q2	$635K	Buy	6,177 +79	+1%	+$8.34K	0.58%	63
2023 Q1	$666K	Sell	6,098 -6,772	-53%	-$749K	0.76%	48
2022 Q4	$1.47M	Buy	12,870 +1,317	+11%	+$109K	1.88%	9
2022 Q3	$715K	Buy	11,553 +4,472	+63%	+$312K	1.06%	27
2022 Q2	$565K	Buy	+7,081	New	+$671K	1.17%	30

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

First National Advisers's HZNP Position: Q4 2023 in Review

First National Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 10,264 shares — an estimated $1.19M sold.

First National Advisers first reported a position in HZNP in Q2 2022 and held it in 6 quarters. The position peaked at $1.47M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

First National Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
First National Advisers sold 10,264 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.19M.
First National Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 6 quarters.
First National Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.47M in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on First National Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.